Videos

Experts discuss the most common adverse events associated with the FOLFOX regimen and effective strategies for early detection and management.

Experts discuss Robert’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment approaches and challenges.

Key opinion leaders discuss experiences managing weight gain with lorlatinib, addressing its impact on quality of life versus treatment benefits.

Key opinion leaders explore strategies for managing neurotoxicity in patients on ALK inhibitors, emphasizing monitoring practices and balancing symptom management with treatment efficacy.

Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.

Panelists discuss how their lived experiences and insights as patients should inform research priorities, treatment development, and care delivery improvements while sharing hopes for a future cure that would eliminate ongoing disease management needs and allow greater life flexibility.

Panelists discuss how they maintain treatment adherence through digital health apps, calendar reminders, and symptom journals while working closely with their care teams to address uncertainties and make informed decisions about therapy adjustments, with crucial support from caregivers who help track appointments and provide emotional encouragement throughout their chronic care journey.

Panelists discuss how they navigated initial treatment confusion by seeking clarification from healthcare providers, consulting patient resources, and connecting with support groups to better understand their care journey.

Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time with each patient to provide the best care.

The conversation explores strategies for collaboration between academic centers and community practices in delivering optimal long-term care for CAR-T patients, highlighting useful resources for community oncologists and approaches to managing referrals for follow-up care.

The discussion focuses on essential components of patient education and support for long-term CAR-T survivors, addressing strategies to sustain quality of life, manage late therapy effects, and meet the distinct long-term care needs of ide-cel and cilta-cel recipients.

Dr Mohan engages with Dr Mann, Nurse Brigle, Nurse Distaso, and Dr Nadeem to explore challenges in the referral process for bispecific therapy, including local health care barriers, and strategies for ensuring consistent patient education and support when care is shared between community and academic centers.

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially serious toxicities that should be closely monitored.

Key opinion leaders focus on educating patients about potential side effects of lorlatinib and other ALK inhibitors, including guidance on when to contact their care team.

Medical experts provide their final insights surrounding quality of life amid treatment for metastatic non-small cell lung cancer.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN

Medical experts discuss strategies for managing adverse events associated with KRAS-targeted therapies, addressing monitoring challenges with oral medications and balancing symptom management with treatment efficacy.

The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, RN.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

This video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.

The discussion highlights the role of multidisciplinary collaboration in CAR-T patient care, emphasizing effective coordination among specialists, primary care providers, and community oncologists, and strategies for ensuring consistent communication and continuity of care for patients in remote locations.

The discussion delves into long-term monitoring strategies for CAR-T patients, exploring differences between academic and community settings and emerging long-term adverse effects as clinical experience with CAR-T therapy grows.

Dr Mohan discusses with Nurse Goff, Dr Mohan, and Dr Nadeem strategies for maintaining continuity of care and communication between community centers and academic institutions during bispecific therapy, as well as best practices for transitioning care back to the community center after therapy administration.

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for effectively initiating these discussions with patients.

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

Key opinion leaders compare osimertinib's adverse event profile to other EGFR inhibitors, highlighting specific challenges and benefits observed in clinical practice

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

Key opinion leaders highlight effective multidisciplinary strategies for managing the diverse range of side effects associated with EGFR inhibitors.